Pediatric Cardiology and Cardiac Surgery
Online ISSN : 2187-2988
Print ISSN : 0911-1794
ISSN-L : 0911-1794
Case Report
Subcutaneous Immunoglobulin (SCIG) Home Therapy for Treatment of Hypogammaglobulinemia due to Protein-losing Enteropathy (PLE) after Total Cavopulmonary Connection
Yuya YamadaTakaya OtaYoji NomuraNobuo TauchiEiki NishiharaKenji Kuraishi
Author information
JOURNAL OPEN ACCESS

2016 Volume 32 Issue 5 Pages 432-436

Details
Abstract

We report on a patient with protein-losing enteropathy (PLE) after undergoing total cavopulmonary connection (TCPC) operation who was introduced to subcutaneous immunoglobulin (SCIG) home therapy as immunoglobulin G (IgG) replacement therapy. The patient was a 21-year-old man with hypoplastic left heart syndrome who developed edema and ascites secondary to PLE 5 years after the TCPC operation. When he was 15-years-old, intravenous immunoglobulin (IVIG) was administered for the treatment of hypogammaglobulinemia. SCIG home therapy was introduced when he was 20 years old. The serum IgG level did not increase with the initial SCIG dose (8 g/week); therefore, we increased the SCIG dose (16 g/week). After SCIG administration, the serum albumin level was reduced from 2.7 to 2.4 g/dL, IgG level increased from 370 to 484 mg/dL, and the total duration of the hospital stay was shortened from 4.7 to 1.2 d/month. With regard to adverse events, a local reaction was observed at the subcutaneous infusion site, but this improved with time. These findings suggest that SCIG home therapy is effective in increasing and maintaining serum IgG levels and avoiding hospitalization. The appropriate SCIG dose for patients with PLE is unknown. We believe that this should be considered on a case-by-case basis depending on the severity of each case.

Content from these authors
© 2016 Japanese Society of Pediatric Cardiology and Cardiac Surgery
Previous article Next article
feedback
Top